Whether due to a slow metabolism, hormonal imbalances, or other medical factors, weight loss can feel like an uphill battle
While sermorelin stimulates your pituitary gland to release natural growth hormone, testosterone helps increase muscle mass, libido, and mood stability
Your intake form helps our medical team guide your selection, or you can book a follow-up consultation for more detailed recommendations
2018, p
FRIDAY, March 6, 2026 (HealthDay News) -- Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.Muaaz Wajahath, from the Michigan State University College of Human Medicine in East Lansing, and colleagues evaluated the five-year risk for osteoporosis, gout, and osteomalacia in adults with both type 2 diabetes and obesity treated with GLP-1 RAs (semaglutide, liraglutide, dulaglutide, or exenatide) compared with matched controls (73,483 per group).The researchers found that at five years, patients exposed to GLP-1 RAs had a significantly increased risk for osteoporosis compared with controls (4.1 versus 3.2 percent
